{'fraction_non_alphanumeric': 0.06843800322061191, 'fraction_numerical': 0.033816425120772944, 'mean_word_length': 4.573991031390134, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
406 PROPHYLACTIC INDOMETHACIN: EFFECTS ON RENAL FUNCTION

This controlled, double-blind, study assessed the renal impact of early (< 12 hr postnatal age) indomethacin [I], for prevention of patent ductus arteriosus (PDA), in O2 dependent inborn infants with birth weights (BW)≤1300 gm. Fifty infants randomly received 3 IV doses of [I] or placebo [P] at 12 hr intervals. Dose1 (D1) was 0.2 mg/kg;D2 and D3 were 0.1 mg/kg each. Fluid balance, serum sodium (Na), potassium (K), creatinine (Cr), blood urea nitrogen (BUN) and fractional Na excretion (FENa) were evaluated pre-D1, 6-12 hr post-D1, 12-36 hr post-D3, and 1 wk post-D3. Timed urine specimens were used to derive Cr clearance (CCr) post-D3 and 1 wk post-D3. The 25 infants in each group were comparable in BW, gestational age, APGARs, pH and base excess at study entry. [I]-treated infants had reduced urine output (UO) in the 12 hr period following D1 that was no longer evident post-D3. Fluid intake, Na, K, BUN, Cr, FENa, and CCF were similar throughout the study. Renal data (x±SEM) revealed:In contrast to reports of renal dysfunction induced by indomethacin therapy for symptomatic PDA, early [I] appears to alter renal function minimally in prematures without significant PDA.